Literature DB >> 8665232

Liver metastases from colorectal cancer: lessons from past and present clinical studies.

I Taylor1.   

Abstract

In patients with primary colorectal cancer the development of liver metastases has traditionally been equated with imminent demise. This metastatic event is remarkably common; indeed, liver metastases are present in some 25 per cent of patients at the time of initial colorectal resection and over 50 per cent of patients will eventually develop them. Some 90 per cent of patients who die from colorectal cancer have liver metastases. There are few cancers in which the metastatic pattern has such a high degree of predictability. Information from past and present clinical studies should, therefore, provide a basis for logical approaches to prevention and treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8665232     DOI: 10.1002/bjs.1800830406

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  17 in total

1.  Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.

Authors:  Nozomu Machida; Kouji Yoshizaki; Narikazu Boku; Kentaro Yamazaki; Yusuke Onozawa; Akira Fukutomi; Hirofumi Yasui; Keisei Taku
Journal:  Int J Clin Oncol       Date:  2012-02-25       Impact factor: 3.402

Review 2.  Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases.

Authors:  Chad G Rusthoven; Tracey E Schefter
Journal:  Hepat Oncol       Date:  2013-12-20

3.  Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.

Authors:  Jeong Won Lee; Seok-Ki Kim; Sang Mi Lee; Seung Hwan Moon; Tae-Sung Kim
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

4.  Microcirculation and excretory function of the liver under conditions of carbon dioxide pneumoperitoneum.

Authors:  I Leister; P Schüler; B Vollmar; L Füzesi; E Kahler; H Becker; P M Markus
Journal:  Surg Endosc       Date:  2004-06-23       Impact factor: 4.584

5.  The Impact of Advancing Age on Recurrence and Survival Following Major Hepatectomy for Colorectal Liver Metastases.

Authors:  Richard Bell; Sanjay Pandanaboyana; Saira Nisar; Vivek Upasani; Giles Toogood; J Peter Lodge; K Raj Prasad
Journal:  J Gastrointest Surg       Date:  2016-10-21       Impact factor: 3.452

6.  Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer.

Authors:  Hisashi Onodera; Akira Mori; Satoshi Nagayama; Akihisa Fujimoto; Tsuyoshi Tachibana; Yoshikuni Yonenaga; Tatsuaki Tsuruyama
Journal:  Int J Colorectal Dis       Date:  2005-04-22       Impact factor: 2.571

7.  In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy.

Authors:  Louis-Bastien Weiswald; Jean-Marc Guinebretière; Sophie Richon; Dominique Bellet; Bruno Saubaméa; Virginie Dangles-Marie
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

8.  The phosphodiesterase 3 inhibitor cilostazol does not stimulate growth of colorectal liver metastases after major hepatectomy.

Authors:  Moritz J Strowitzki; Stefan Dold; Maximilian von Heesen; Christina Körbel; Claudia Scheuer; Mohammed R Moussavian; Martin K Schilling; Otto Kollmar; Michael D Menger
Journal:  Clin Exp Metastasis       Date:  2014-07-23       Impact factor: 5.150

9.  The impact of carbon dioxide and helium insufflation on experimental liver metastases, macrophages, and cell adhesion molecules.

Authors:  C N Gutt; T Gessmann; P Schemmer; A Mehrabi; Th Schmandra; Z-G Kim
Journal:  Surg Endosc       Date:  2003-07-21       Impact factor: 4.584

10.  Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.

Authors:  S B Hosch; P Scheunemann; M Lüth; S Inndorf; N H Stoecklein; A Erbersdobler; A Rehders; M Gundlach; W T Knoefel; J R Izbicki
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.